Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardian Pharmacy Services (GRDN) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Guardian Pharmacy Services (GRDN) over the last 3 years, with Q3 2025 value amounting to $58.4 million.

  • Guardian Pharmacy Services' Operating Expenses fell 6473.1% to $58.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.6 million, marking a year-over-year decrease of 2715.24%. This contributed to the annual value of $307.3 million for FY2024, which is 8360.64% up from last year.
  • As of Q3 2025, Guardian Pharmacy Services' Operating Expenses stood at $58.4 million, which was down 6473.1% from $55.6 million recorded in Q2 2025.
  • In the past 5 years, Guardian Pharmacy Services' Operating Expenses registered a high of $165.5 million during Q3 2024, and its lowest value of $39.1 million during Q4 2023.
  • Over the past 3 years, Guardian Pharmacy Services' median Operating Expenses value was $51.3 million (recorded in 2025), while the average stood at $63.3 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 18278.43% in 2024, then tumbled by 6473.1% in 2025.
  • Guardian Pharmacy Services' Operating Expenses (Quarter) stood at $39.1 million in 2023, then grew by 28.92% to $50.3 million in 2024, then rose by 15.92% to $58.4 million in 2025.
  • Its last three reported values are $58.4 million in Q3 2025, $55.6 million for Q2 2025, and $51.3 million during Q1 2025.